Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 11/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 11/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 10/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 10/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 9/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15908888 | 1.00 | CHRNB2 (0.38) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL37704 | 1.00 | CHRNB2 (0.38) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL7501464 | 0.79 | HCRTR2 (0.34) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL37905 | 0.77 | CHRNB2 (0.43) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL15908968 | 0.77 | CHRNB2 (0.43) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL37741 | 0.77 | CHRNB2 (0.43) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL15908962 | 0.72 | L3MBTL1 (0.47) | — | |
| SCHEMBL19771723 | 0.67 | HTT (0.33) | — | |
| SCHEMBL21797739 | 0.66 | CHRNB2 (0.31) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL21797663 | 0.66 | CHRNB2 (0.31) | CHRNB2CHRNA4CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110294854-A1 | SUBSTITUTED OCTAHYDROCYCLOPENTA[c]PYRROLES AS CALCIUM CHANNEL MODULATORS | ABBOTT LABORATORIES (US) | 2011-12-01 | — | — | US | claimed |
| US-8796470-B2 | Substituted octahydrocyclopenta[c]pyrroles as calcium channel modulators | ABBVIE INC. (US) | 2014-08-05 | — | — | US | disclosed |
| WO-2011149993-A2 | SUBSTITUTED OCTAHYDROCYCLOPENTA[c]PYRROLES AS CALCIUM CHANNEL MODULATORS | ABBOTT LABORATORIES (US) | 2011-12-01 | — | — | WO | disclosed |
| US-20110294854-A1 | SUBSTITUTED OCTAHYDROCYCLOPENTA[c]PYRROLES AS CALCIUM CHANNEL MODULATORS | ABBOTT LABORATORIES (US) | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294854-A1 | SUBSTITUTED OCTAHYDROCYCLOPENTA[c]PYRROLES AS CALCIUM CHANNEL MODULATORS | ORAI1, CACNA1E, RYR1 | CHRNB2 583/4885CHRNA4 484/4885CHRNB4 799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.